Highlights Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 13:40:10 16/01/2026 GMT			5-day change	1st Jan Change
24.22 ^EUR	+0.10%		-6.59%	-5.86%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Highlights

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG and Bioeq AG Announce the U.S. Food and Drug Administration Approves Nufymco®?	CI
12-09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
12-09	Formycon AG and Zydus Lifesciences Limited Partner for Exclusive Licensing and Supply Agreement of FYB206, a Biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	CI
12-09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
12-09	Formycon Ag and Zydus Lifesciences Limited Enter into Strategic Partnership for the Exclusive Licensing and Supply of Checkpoint Inhibitor Fyb206	CI
12-04	Formycon AG and MS Pharma Sign Exclusive Commercialization Partnership for Keytruda®? Biosimilar Candidate FYB206 for the MENA Region	CI
12-04	Formycon, MS Pharma Enter Licensing Deal for Keytruda Biosimilar in MENA	MT
12-04	Newcomers TKMS and Aumovio Join MDax; Dax Remains Unchanged	RE
11-24	Formycon Appoints NTC as Exclusive Commercial Partner for Eylea Biosimilar in Italy	MT
11-24	Formycon AG and NTC S.r.l. Jointly Announce Eylea Biosimilar FYB203/Baiama®? in Italy	CI
11-20	Formycon Ag and Bioeq Ag Jointly Announce an Agreement with Sandoz Ag for the Commercialization of Epruvy in Germany	CI
11-17	Formycon AG Announces Biosimilar Candidate FYB208 For Dupixent	CI
11-13	Formycon Maintains Annual Targets, Anticipates Year-End Surge	DP
11-13	Formycon 9m revenue EUR 19.5 million	RE
11-13	Formycon Confirms Forecast Amid Revenue Slump and Higher Operating Loss	DP
11-13	Formycon AG Confirms Earnings Guidance for the Year 2025	CI
21/10/25	Formycon AG, Bioeq AG and Teva Pharmaceutical Industries Ltd. Jointly Announce the Launch of FYB201/Ranivisio as the First Ranibizumab Biosimilar Available in Pre-Filled Syringe	CI
02/10/25	Formycon Settles Patent Disputes with Regeneron Over Eylea Biosimilar in US	MT
17/09/25	Formycon benefits from further distribution agreement for Eylea biosimilar	DP
17/09/25	Formycon Enlists Horus Pharma to Commercialize Eylea Biosimilar in Europe	MT
13/08/25	Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2025	CI
13/08/25	Formycon AG Confirms Earnings Guidance for the Full Year 2025	CI
13/08/25	Formycon Figures Deliver Bitter Pill for Investors	DP
13/08/25	Formycon Confirms Forecast Despite Revenue Drop - Shares Under Pressure	DP

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Highlights

Filters